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Vpu proteins of pandemic HIV-1 M strains degrade
the viral receptor CD4 and antagonize human tetherin
to promote viral release and replication. We show that
Vpus from SIVgsn, SIVmus, and SIVmon infecting
Cercopithecus primate species also degrade CD4
and antagonize tetherin. In contrast, SIVcpz, the
immediate precursor of HIV-1, whose Vpu shares
a common ancestry with SIVgsn/mus/mon Vpu,
uses Nef rather than Vpu to counteract chimpanzee
tetherin. Human tetherin, however, is resistant to
Nef and thus poses a significant barrier to zoonotic
transmission of SIVcpz to humans. Remarkably,
Vpus from nonpandemic HIV-1 O strains are poor
tetherin antagonists, whereas those from the rare
group N viruses do not degrade CD4. Thus, only
HIV-1 M evolved a fully functional Vpu following the
three independent cross-species transmissions that
resulted in HIV-1 groups M, N, and O. This may
explain why group M viruses are almost entirely
responsible for the global HIV/AIDS pandemic.
INTRODUCTION
Primate lentiviruses such as HIV and SIV encode several acces-
sory proteins. These include Vif, Vpr, Vpu, Vpx, and Nef and are
often dispensable for viral growth in vitro. However, they are
important for viral replication in vivo because they counteract
host restriction factors, enhance viral replication and virion infec-
tivity, or facilitate viral evasion of the adaptive immune response
(reviewed in Malim and Emerman, 2008). Vif, vpr, and nef areCell Hostpresent in the genomes of all primate lentiviruses. In contrast,
vpu genes were initially only found in HIV-1 and its precursor
SIVcpz from chimpanzees (Pan troglodytes), but not in HIV-2
or other SIV strains (Cohen et al., 1988; Huet et al., 1990; Gao
et al., 1999; Santiago et al., 2003). Subsequently, molecular
characterization of SIVs from additional primate species re-
vealed that the genomes of SIVgsn, SIVmon, SIVden, and
SIVmus from greater spot-nosed (Cercopithecus nictitans),
mona (C.mona), Dent’smona (C.denti), and Mustached monkeys
(C. cephus), as well as SIVgor from gorillas (Gorilla gorilla gorilla),
also carry vpu genes (Barlow et al., 2003; Courgnaud et al.,
2002, 2003; Dazza et al., 2005; Takehisa et al., 2009). SIVcpz,
which gave rise to pandemic (M, main) and nonpandemic (O,
outlier and N, non-M, non-O) groups of HIV-1 and also to SIVgor
(which is closely related to HIV-1 O; Van Heuverswyn et al., 2006),
is the product of successive cross-species transmission and
recombination events involving precursors of today’s SIVgsn/
mus/mon/den and SIVrcm from red-capped mangabeys
(Cercocebus torquatus) (Bailes et al., 2003). Thus, all vpu genes
likely originated from a common ancestor of the SIVgsn/mus/
mon/den lineage of primate lentiviruses (Kirchhoff, 2009).
Vpu is an80 amino acid integral class I membrane phospho-
protein (Cohen et al., 1988; Maldarelli et al., 1993). Studies per-
formed with HIV-1 NL4-3 Vpu have established two main func-
tions. First, Vpu induces the degradation of the primary viral
receptor CD4 by a multistep process that involves direct binding
of Vpu to the cytoplasmic tail of CD4 in the endoplasmic retic-
ulum (Bour et al., 1995; Margottin et al., 1998; Willey et al.,
1992). Second, Vpu promotes the release of progeny virions
from HIV-1-infected human cells (Strebel et al., 1988; Klimkait
et al., 1990; Gottlinger et al., 1993) by antagonizing a recently
identified restriction factor termed tetherin (also known as
CD317, BST2, or HM1.24) that is induced by interferon-a and
results in the ‘‘tethering’’ of nascent virions to the cellular plasma& Microbe 6, 409–421, November 19, 2009 ª2009 Elsevier Inc. 409
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Hydrophobic TM domain α-helix P P           ”ß-turn”
HIV-1 M   NL4-3 MQPI----IVAIVALVVAIIIAIVVWSIV----IIEYRKILRQR----KIDRLIDR-LIERAEDSGNESEGEVSALVEMGVEMGHHAPWDIDDL
HIV-1 M   89-6   MLSLQ---ILAIVALVVAAIIAIVVWSIV----FIEYRKILRQR----KIDRLIDR-IREREEDSGNESEGDQEELA-AL-ERGHLAPWDVDDL
HIV-1 M   YU-2   MQSLQ---VLAIVALVVATIIAIVVWTIV----FIEYRKILRQR----KIDRLINR-ITERAEDSGNESDGDQEELS-ALVERGHLAPWDVDDL
HIV-1 M   JR-CSF MQPLQ---ILAIVALVVAGIIAIIVWSIV----LIEYRKILRQR----KIDRLIDK-IRERAEDSGNESEGDQEELS-ALVERGHLAPWDINDL
HIV-1 O   13127  MHYRD---LLTLIAISALLFANVVVWMFV-LKKYLEQKKQDRREK---EILKRLRR-LREKGDDSDYDSNGEEEQEVMDLVHSHGFDNPMFEL
HIV-1 0   9435   MHYKD---LVIIIIISALLLVNVLIWMFN-LRKYLEQKEQERRER---EIIERLRR-IREIRDDSDYESNKEEEQEVMGLVHAHGFDNPMFEL
HIV-1 O   HJ001  MHNKD---LLIIIIVSALLLINVILWMFN-LRTYLKQKRQDRRER---EVIERIRR-IRQVREDSDYESNGEEEQEVMDLVHSHGFDNPMFEL
HIV-1 N   YBF30  MLS------LGFIALGAAVSIAVIVWALL----YREYKKIKLQE----KIKHIRQR-IREREEDSGNESDGDAEWLDGDEEWLVTLLSSSKLDQGNWV
HIV-1 N   2693BA MLL------LGFIAVGIAIVIAAIIWVLL----YKEYKKIKLQE----KIRHIRQR-IKDRAEDSDSESDGDAEILATLLSPNKLDQGDWV
HIV-1 N   CK1.62 MLL------LGFIAVGIAIVIAVIIWVLL----YKEYKKIKLQE----EIKHIRQR-IKDRAEDSDSESDGDAEILATFLSPNKLDQGDWV
SIVcpzPtt LB7   MD-LI---ELGLIGLVIELIIVIVVWLKA----YQLYKENIRQK----AINKLIER-IRERGEDSGNESEGDMDELHAILRSGD-PELVLIDN
SIVcpzPtt MB66  MDIVQQ--VGLLVVLIIELVIVIVIWVKV----YKLCKEDRRQK----KIDRLIAR-IRERAEDSGNESDGDTEELQDLITEGDNLMHIGIRDNRNN
SIVcpzPtt MB897 MEIFII---LGLIGIVIELVIAIVVWLKA----YECYKALKRQE----RRDQLIDR-IRERAEDSGNESDGDTEELEAILIPEDRHVLVAIRGY
SIVcpzPtt EK505 MLLLIK---LGFIGLAIETLIVIVVWAIV----YRIYREVKVEE----KISQLRQR-IRDRAEDSGNESDGDAEEL-ANLLPPDRIDQDNWV
SIVcpzPtt MT145  MQLEI----VLIILFIALMLVAIFAWIAA----YKEYKKLQQVR----RIERLQDR-IRSRAEDSGNESDGD-EILLVEELMQVHQHQVNPDWMDRILFW
SIVcpzPtt GAB1  MTLLVG----LVLILVGLIAWNICIWGYIIKWGYRRYKR-HRLET---EIERLNLI-LRERAEDSGNESNGEEEERLEQLIHNYNHNNHFANPMFDL
SIVcpzPts ANT   MTNI-----FEYAFLAFSIVLWIICIPIL----YKLYKIYKQQQIDNKRNQRIIEVLSRRLSIDSAIEEDEE---ADTYYLGSGFANPVYREGDE
SIVcpzPts TAN1  MIKIVVGSVSTNVIGILCILLILIGGGLLI--GIGIRRELERER----QHQRVLERLARRLSIDSGVEEDEE---FNWNNFDPHNYNPRDWI
SIVcpzPts TAN2  MVKLVVGSVLTNVIGIFCILLILIGGGLLI--ITIIKREIERER----QHQRILERLIRRLSIDSGVEEDEE---LNWNNFDPHNYNPRDWI
SIVcpzPts TAN3  MVKIVVGSVLTNVIGAFCILLILIGGGLLI--IAFVRRELERER----QHQRVIERLVRRLSIDSGIDEDEE---LNWNNFDPHNFNPRDWI
SIVgor    CP2139  MHPRD---IIVIIIGITLLAVTVIIWLKIFA-LYL RDRRER------RFFDRLERLLSNKEDEGYESNEEEAAELMEMGNELGFDFNLH
SIVmon    CML1   MNYWWS—LVAITYSLILIALPVAAWAWWR---YYKITKRFKRIDQ---EIQRLIQI-HERRRHDSGV-DTESESEQHEETHGFVNPVFNDDFGEWV
SIVgsn    71    MSAAA---LWWWGAAVITFIYFCLAIFAL----YLAWDKWIKGKP---KIPVAVIR-LVEDDEESGIFEDAS-----SEPNAYGFANPGFEV
SIVgsn    166    MHPAA---VWWWGAAIITFIYLCVALLAL----YLAWDKWVKGKP--KPTQVAVIR-LIEDEEDSGIYDDAS-----SELTGFNGFANPGFEV
SIVmus    1085   MNYWY---LAAVIVTGIYFVIAIFAFVLA----YQRWCKPK-------KVEVSVIRLLEEGDGDSGIFEDAEDDMAESEHHAFANPAFEQ
SIVmus    S1239  MNYWY---LAAALVTGIYFLIALFAFVLA----YQRWCRP--------KVEVSVIRLLEEGDSDSGIFEDAEDEPNGDGHHAFANTAFEQ
SIVmus    S2500  MNWWW---FAAAVVTAIYFVIALVAFVLA----YQRWCQPQKGQ-----VEVNVIRLLEEGDTDSGIFEDAED-----GTDPAHGFLNPAFEL
Figure 1. Alignment of HIV-1 and SIV Vpu Amino Acid Sequences
The NL4-3 Vpu sequence is shown on top for comparison. The hydrophobic transmembrane (TM) domain, the central charged region, the position of two serine
phosphorylation sites, and a b turn motif in the NL4-3 Vpu protein are indicated. Dashes indicate gaps introduced to optimize the alignment. Acidic residues (E, D)
are highlighted in green; basic residues (K, R), blue; hydrophobic residues (I, V, L), orange; and residues that can potentially be phosphorylated (S, T, Y), red.membrane (Neil et al., 2008; Van Damme et al., 2008). Tetherin
has a broad antiviral activity and inhibits the release of various
enveloped viruses (Jouvenet et al., 2009; Kaletsky et al., 2009;
Sakuma et al., 2009). Furthermore, monkey and rodent tetherins
block virion release but are not counteracted by HIV-1 Vpu
(Goffinet et al., 2009; Gupta et al., 2009; McNatt et al., 2009;
Wong et al., 2009).
To date, functional data have almost exclusively been derived
from the Vpu protein of the T cell line adapted HIV-1 NL4-3
molecular clone. It is thus unknown to what extent CD4 degrada-
tion and tetherin antagonism are conserved among the diverse
Vpu proteins found in HIV-1 and SIVs and how Vpu function
evolved following zoonotic transmissions of primate lentiviruses
from monkeys to chimpanzees and, ultimately, to humans. To
address these questions, we analyzed a panel of vpu constructs
representing nearly the entire spectrum of primate lentiviruses
known to encode this accessory gene, i.e., HIV-1 M, HIV-1 O,
HIV-1 N, SIVcpz, SIVgor, SIVgsn, SIVmon, and SIVmus. We
show that all Vpu proteins except those found in HIV-1 group
N degrade human CD4, whereas tetherin is antagonized in
a more species-specific manner. Unexpectedly, we found that
SIVcpz employs Nef rather than Vpu as a tetherin antagonist.
Following transmission of SIVcpz to humans, HIV-1 group M
Vpu and not Nef acquired an antitetherin activity in addition to
its ability to degrade CD4, most likely because the human teth-
erin has a deletion in its cytoplasmic domain that disrupts its
susceptibility to Nef (Zhang et al., 2009). In contrast, Vpus of non-
pandemic HIV-1 group O and N strains that resulted from inde-
pendent zoonotic transmissions (Hahn et al., 2000; Van Heuvers-
wyn and Peeters, 2007) either do not antagonize human tetherin
(group O strains) or are unable to degrade CD4 (group N strains).
Thus, the evolution of a fully functional Vpu protein may have410 Cell Host & Microbe 6, 409–421, November 19, 2009 ª2009 Elsbeen an important prerequisite for the efficient spread of HIV-1
group M in the human population.
RESULTS
Primate Lentiviral Vpus Are Highly Variable but Exhibit
Some Conserved Features
To examine to what extent CD4 degradation and antitetherin
activity are conserved among primate lentiviral Vpus, we
analyzed a large panel of HIV-1 and SIV vpualleles (Table S1 avail-
able online). Our collection included Vpu constructs from 26
strains of HIV-1 group M, 11 strains of HIV-1 O, 3 strains of
HIV-1 N, 6 strains of SIVcpzPtt from central chimpanzees (CPZ),
4 strains of SIVcpzPts from eastern chimpanzees, 1 strain of
SIVgor from a Western lowland gorilla (GOR), 2 strains of SIVgsn
from greater spot-nosed monkeys (GSN), 1 strain of SIVmon from
a mona monkey (MON), and 3 strains of SIVmus from mustached
monkeys (MUS). The HIV-1 group M Vpus included all 9 subtypes,
as well as 10 vpu alleles (8 clade B and 2 clade C) from full-length
infectious molecular clones of transmitted/founder viruses
obtained by single-genome amplification of plasma virion RNA
(Li et al., 2005; Salazar-Gonzalez et al., 2009). Of note, all but
two SIV vpu genes were amplified directly from the blood or fecal
material of naturally infected monkeys or apes (Table S1).
An amino acid alignment of representative primate lentiviral
Vpus shows that they are highly variable. Nonetheless, some
features are usually conserved, including a hydrophobic
N-terminal membrane anchor domain; a putative central
a-helical region with hydrophobic, basic, and acidic residues;
and an acidic C-proximal region (Figure 1). Two serine residues
(S52 and S56) known to be phosphorylated by casein kinase II
and required for CD4 degradation by NL4-3 Vpu (Schubert andevier Inc.
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Tetherin Antagonism by Primate LentivirusesFigure 2. Suppression of CD4 Surface Expression by HIV-1 and SIV Vpus
(A) FACS analysis of 293T cells cotransfected with a CD4 expression vector and pCGCG plasmids expressing GFP alone (GFP only) or together with the indicated
vpu alleles. Constructs expressing the NL4-3 Nef and the mutant NL4-3 S52A Vpu were used as positive and negative controls, respectively.
(B) Reduction of Vpu-mediated CD4 expression in 293T cells. Shown is the reduction in the levels of CD4 cell surface expression relative to those measured in
cells transfected with the GFP only control vector. The range of GFP expression used for the calculation is indicated in (A). Each symbol represents one of the
57 vpu alleles examined (Table S1) or the indicated controls. Shown are average values derived from three experiments. The GFP control is color coded green;
vpu alleles derived from SIVgsn, SIVmon, and SIVmus, gray; SIVcpz and SIVgor, magenta; HIV-1 M, red; O, blue; and N, orange.Strebel, 1994; Paul and Jabbar, 1997) were present in all HIV-1
and SIVcpzPtt Vpus. In the remaining Vpus, the number and
location of serine residues varied, although at least one potential
serine phosphorylation site was always preserved (Figure 1).
Thus, despite their exceedingly high variability, primate lentiviral
Vpus exhibit common sequence signatures.
All Vpu Proteins Except Those from HIV-1 Group N
Induce CD4 Degradation
To determine which primate lentiviral Vpus prevent cell surface
expression of CD4, we cotransfected 293T cells with vectors
coexpressing Vpu and GFP (or GFP alone for control) together
with a human (HU) CD4 expression construct. In the absence
of Vpu, cells expressed high levels of CD4 and GFP (Figure 2A).Cell HostHowever, upon coexpression of most Vpus, CD4 surface
expression was markedly decreased (examples are shown in
Figure 2A). This effect was Vpu specific because it was abro-
gated by a single S52A mutation in the cytosolic domain of the
HIV-1 NL4-3 Vpu, previously shown to be critical for CD4 degra-
dation (Schubert and Strebel, 1994; Paul and Jabbar, 1997).
Quantitative analysis of CD4 surface levels (Figure 2B) showed
that most SIVgsn, SIVmon, SIVmus, SIVcpz, and SIVgor, as
well as HIV-1 M and O Vpus, reduced CD4 cell surface expres-
sion by more than 80% (Figure 2B). In striking contrast, each
of three HIV-1 group N Vpu proteins lacked this function
(Figure 2B). These functional differences were statistically highly
significant (p < 0.0001). Analysis of Vpus containing a C-terminal
AU-1-tag confirmed these results and showed that all but one& Microbe 6, 409–421, November 19, 2009 ª2009 Elsevier Inc. 411
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and data not shown). These results show that the ability to block
CD4 cell surface expression is highly conserved among primate
lentiviral Vpus, with the notable exception of HIV-1 N Vpu, which
lacks this function (Figure 2B).
SIVcpz, SIVgor, and HIV-1 Group O Vpus Do Not
Efficiently Antagonize Tetherin
It has recently been shown that the HIV-1 NL4-3 Vpu antago-
nizes tetherin in a species-specific manner, i.e., it exhibited
activity against human, but not monkey (i.e., rhesus macaque
[RM] and African green monkey [AGM]) or rodent, tetherins
(Goffinet et al., 2009; Gupta et al., 2009; McNatt et al., 2009).
To determine the antitetherin activity of other primate lentiviral
Vpus, we generated vectors that expressed GSN, MON, MUS,
CPZ, GOR, HU, AGM, and RM tetherin molecules (Table S2).
As shown in Figure 3A, the sequence of the transmembrane
(TM) domain of tetherin, which has been evolving under positive
selection and determines its susceptibility to HIV-1 NL4-3 Vpu
(McNatt et al., 2009; Gupta et al., 2009), varies substantially
between higher primates and monkeys but is conserved
between humans, gorillas, and chimpanzees (except for
a V35M variation between HU and CPZ tetherins; Figure 3A). In
comparison, the TM domains of the six monkey tetherin
sequences differed at a total of four amino acid positions. All
tetherin proteins were expressed and suppressed HIV-1 release
in the absence of Vpu (Figure S2).
To test whether the various HIV-1 and SIV Vpus are capable of
counteracting tetherins from their respective hosts, as well as
those from other species, we measured infectious virus yields
from 293T cells following cotransfection of a vpu-deleted
(DVpu) HIV-1 proviral construct (Rucker et al., 2004) with Vpu
and tetherin expression plasmids. Our data showed that only
HIV-1 Vpus were effective antagonists of HU, CPZ, and GOR
tetherins (Figure 3B). In comparison, SIVgsn, SIVmon, and
SIVmus Vpus counteracted the tetherins of their respective
host, as well as other monkey species (Figure 3B). The exception
was SIVmon CML1 Vpu, which was inactive against the MUS
tetherin, which differs from the other monkey tetherins by
a L36F substitution and a single amino acid deletion (DL42) in
the TM domain (Figures 3A and 3B). Thus, HIV-1 group M
Vpus potently antagonized tetherins of apes and humans but
were less effective against the monkey restriction factors,
whereas SIVgsn, SIVmon, and SIVmus Vpus showed the oppo-
site phenotype. Of interest, the HIV-1 JR-CSF and YU-2 Vpus
exhibited some activity against GSN and AGM tetherins (Fig-Cell Hosture 3B), indicating that certain HIV-1 Vpus have a broader antite-
therin activity than the NL4-3 Vpu (Goffinet et al., 2009; Gupta
et al., 2009; Jia et al., 2009; McNatt et al., 2009). In agreement
with previous studies (McNatt et al., 2009), an exchange of the
TM domain in HU tetherin with that of AGM or RM rendered it
resistant to HIV-1 Vpus but conferred sensitivity to SIVmon and
SIVmus Vpus (Figure S3).
Whereas the functional profiles of HIV-1, SIVgsn, SIVmon, and
SIVmus Vpus were as expected, the observed antitetherin activ-
ities of ape virus Vpus came as a surprise. All SIVcpz Vpus,
including those derived from the closest relatives of the HIV-1
group M (i.e., LB7, MB897, and MB66) (Keele et al., 2006), failed
to antagonize all eight different tetherins, including those derived
from their cognate CPZ host (Figure 3B). Similarly, the Vpu
protein of SIVgor had only poor antitetherin activity. These
results were confirmed by expressing the various Vpu proteins
in cis in the context of infectious HIV-1 molecular clones, using
both tetherin-transfected 239T cells as well as HeLa cells ex-
pressing endogenous tetherin (see Supplemental Results and
Figures S4, S5, and S6). To control for intracellular viral gene
expression, we also examined the antitetherin activity of primate
lentiviral Vpus by western blot analysis. The results confirmed
that HIV-1 Vpus efficiently counteracted HU and CPZ tetherins
but were less effective against those of AGM or RM, whereas
Vpu proteins from SIVgsn and SIVmus showed the opposite
phenotype. They also confirmed that SIVcpz Vpus lack signifi-
cant antitetherin activity (Figure S7). Importantly, the western
blots also demonstrated that the various Vpus acted specifically
at the level of virion release into the culture supernatants and did
not influence cell-associated levels of p24 antigen expression.
Our finding that SIVcpz Vpus are very poor tetherin antago-
nists suggested that HIV-1 group M Vpus gained antitetherin
activity during adaptation to the new human host. Thus, we
next examined whether Vpus from nonpandemic HIV-1 groups
O and N strains (which represent independent cross-species
transmissions) (Hahn et al., 2000; Van Heuverswyn and Peeters,
2007) also evolved the capability of antagonizing HU tetherin.
Strikingly, we found that (similarly to SIVcpz and SIVgor Vpus)
HIV-1 group O Vpus generally displayed little if any activity
against the human tetherin (Figure 3C). In contrast, one HIV-1
group N Vpu (YBF30) efficiently counteracted HU tetherin,
whereas two others had more modest effects (Figure 3C). These
results were confirmed at various levels of HU tetherin expres-
sion (Figure S8). Thus, only HIV-1 group M and N, but not
HIV-1 group O, Vpus have acquired significant antitetherin
activity during viral adaptation to the human host.Figure 3. Tetherin Antagonism by Primate Lentiviral Vpu Proteins
(A) Alignment of tetherin amino acid sequences from humans (HU), chimpanzees (CPZ), gorillas (GOR), Greater spot-nosed monkeys (GSN), Mustached monkeys
(MUS), Mona monkeys (MON-L, C. mona lowei), African green monkeys (AGM), and rhesus macaques (RM). Amino acid identity is indicated by dots and gaps by
dashes. Differences between HU and CPZ tetherins are highlighted by yellow boxes and variations in the TM domain of monkey tetherins by gray boxes. Known
domains, the serine GPI anchor site (red box), and two potential glycosylation sites (underlined) are indicated.
(B) Effect of various Vpus on infectious virus release in the presence of the indicated tetherin molecules. The 293T cells were cotransfected with HIV-1DVpu NL4-3
(2 mg), pCGCG vectors expressing GFP alone or together with Vpu (500 ng), and tetherin expression constructs (50 ng). Viral supernatants were obtained 2 days
later and used to measure the quantity of infectious HIV-1 in the culture supernatants by infecting TZM-bl indicator cells. Shown are average values ± SD (n = 3)
of infectious virion yield relative to those obtained in the absence of tetherin expression vector (100%). The results were confirmed in at least two independent
experiments.
(C) Infectious virus release from 293T cells expressing vpu alleles from the indicated primate lentiviruses and tetherins from their respective host species. The
experiments were performed as described in (B). Each symbol represents the average infectious virus release (n = 3) obtained in the presence of one of the
55 individual vpu alleles analyzed.& Microbe 6, 409–421, November 19, 2009 ª2009 Elsevier Inc. 413
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Tetherin Antagonism by Primate LentivirusesNef Proteins from SIVcpz and SIVgor, but Not from HIV-1
Group O, Antagonize Tetherin
Recently, it has been shown that the Nef proteins of some SIVs
that lack a vpu gene (i.e., those of SIVsmm/mac, SIVagm, and
SIVblu) counteract tetherin (Jia et al., 2009; Zhang et al., 2009).
We therefore examined whether SIVcpz, SIVgor, and HIV-1
group O employ Nef rather than Vpu to antagonize this restriction
factor. Because primate lentiviral Nef proteins enhance virion
infectivity (Mu¨nch et al., 2007), it was expected that expression
of Nef would enhance the infectious virus yield, but not p24
antigen release, in the absence of tetherin (examples shown in
Figure S9). To account for this confounding variable, we normal-
ized all infectious virus yields to that obtained in the presence of
Nef but in the absence of tetherin (100%). After this adjustment,
the relative levels of virus release measured by infectivity assays
and by p24 antigen ELISA correlated extremely well (R2 = 0.93;
Figure S9). We also measured the levels of cell-associated p24
expression by ELISA and western blot and found that neither
Nef nor tetherin affected these values.
First, we examined whether HIV-1, SIVcpz, and SIVgor Nefs
(Table S3) antagonize tetherin from apes and humans by
cotransfecting 293T cells with an HIV-1 proviral construct
lacking vpu and nef, tetherin expression vectors, and constructs
expressing various Nef proteins. The results demonstrated that
SIVcpz and SIVgor Nefs antagonize the tetherin molecules
from their cognate hosts, but not the tetherin variant found in
humans (Figure 4A). Insertion of five amino acids (DDIWK) that
are missing in the cytoplasmic domain of HU tetherin
(Figure 3A) and are known to confer sensitivity to SIVmac and
SIVagm Nef (Jia et al., 2009; Zhang et al., 2009) fully restored
its susceptibility to SIVcpz and SIVgor Nef antagonism (HU-INS;
Figure 4A). The disruptive effect of the N-terminal deletion in HU
tetherin was highly significant (p < 0.0001). Some HIV-1 Nefs dis-
played modest activities against the CPZ, GOR, and HU-INS
tetherins but did not antagonize HU tetherin. The SIVgor Nef
was more effective against the GOR tetherin than any of
six SIVcpz Nefs. Of note, the GOR and CPZ tetherin proteins
differ at only two amino acid positions in the cytoplasmic
domain (D15A and W17L) at the same location that governs
sensitivity to other Nef proteins (Figure 4A). This strongly
suggests that SIVgor Nef has specifically adapted to antagonize
tetherin in gorillas. To confirm these findings, we generated
vpu-defective mutants of replication-competent HIV-1 NL4-3
proviral constructs that coexpress GFP and different HIV-1 and
SIVcpz nef alleles from bicistronic RNAs (Schindler et al., 2006)
and analyzed viral protein expression and release using westernCell Hostblot analyses. Our data confirmed that all SIVcpz Nefs antago-
nize CPZ (but not HU) tetherin (Figure 4B). Of note, Nef proteins
from other SIVs that encode Vpu proteins, i.e., SIVgsn, SIVmon,
and SIVmus, did usually not counteract tetherins from their
respective hosts (Figure 4C). In agreement with published data
(Jia et al., 2009; Zhang et al., 2009), we found that the nef
alleles from SIVmac and SIVagm antagonize RM and AGM
tetherins, albeit less efficiently than SIVcpz Nefs (Figure 4C and
data not shown).
To detect possible weak antitetherin activities, we next
compared the effects of various primate lentiviral vpu and nef
alleles on virus release at different doses of plasmids expressing
the tetherins from their respective hosts. These titration experi-
ments confirmed that SIVgsn, SIVmus, and SIVmon use mainly
Vpu to antagonize tetherin (Figure 5A). The exception was
SIVgsn116 Nef, which also displayed significant antitetherin
activity, suggesting that this primate lentivirus may use both
accessory proteins to counteract this restriction factor. The titra-
tion analyses also confirmed that SIVcpz and SIVgor use Nef and
HIV-1 groups M and N use Vpu to antagonize tetherin (Figures 5A
and 5B). We also assessed whether HIV-1 O Nefs counteract HU
tetherin at lower concentrations because a weak enhancement
of infectious virus release in the presence of HU tetherin was
observed in some experiments (Figure 5B). These titration anal-
yses showed that HIV-1 group O Nefs are just as inactive against
HU tetherin as those of SIVcpz (Figure 5C). Moreover, HIV-1
group O Nefs were less potent antagonists of CPZ tetherin
than were SIVcpz Nefs (Figures 4A and 5C). Thus, HIV-1 group
O strains appear to have lost some of their Nef-associated
anti-CPZ-tetherin activity following transmission to humans.
Taken together, our results demonstrate that SIVcpz and SIVgor
(but not HIV-1 groups M, N, and O) use Nef rather than Vpu to
antagonize tetherin.
DISCUSSION
CD4 Degradation and Tetherin Antagonism Are
Conserved among Primate Lentiviruses
In this study, we examined the evolution of Vpu function in the
primate lentiviruses whose ancestors gave rise to HIV-1. We
show that the two major functions of the HIV-1 NL4-3 Vpu
protein, i.e., CD4 degradation and enhancement of virion release
by counteracting tetherin, are conserved in other vpu-containing
nonhuman primate lentiviruses (summarized in Figure 6A). None-
theless, important differences were noted. First, Vpu appears to
require some host-specific adaptation in order to be an effectiveFigure 4. Tetherin Antagonism by Primate Lentiviral Nef Proteins
(A) Infectious virus and p24 antigen yield from 293T cells cotransfected with the proviral HIV-1 NL4-3 DVpuDNef construct (Rucker et al., 2004) containing dis-
rupted vpu and nef genes (2 mg), pCGCG vectors expressing the indicated nef alleles, or the NL4-3 Vpu protein (500 ng) in combination with plasmids expressing
the HU, CPZ, or GOR tetherins or an Hu tetherin variant in which the N-terminal deletion was restored (HU-INS) (50 ng). (Top) The average values derived from
triplicate infections of TZM-bl indicator cells. (Bottom) The quantity of p24 antigen in the culture supernatant. All values are shown relative to those obtained in the
absence of tetherin expression vector (100%). Levels of cellular p24 expression did not differ significantly (data not shown).
(B) Western blot analysis of cell and virion lysates following cotransfection of 293T cells with vpu-defective proviral DVpu/Nef/GFP HIV-1 NL4-3 constructs
expressing the indicated nef alleles and 50 ng of empty vector (control) or HU or CPZ tetherin-HA expression plasmids. Cell and virion lysates were probed
with an anti-HIV-1 capsid p24 monoclonal antibody. A proviral HIV-1 NL4-3 construct containing defects in both vpu and nef genes was used in the ‘‘none’’
and ‘‘control’’ lanes. Sup., cell culture supernatant.
(C) Infectious virus release from 293T cells expressing nef alleles from the indicated primate lentiviruses and tetherins from their respective host species. The
experiments were performed as described in (A). The symbols represent the average infectious virus release (n = 3) obtained in the presence of one of the
25 nef alleles analyzed. ***p < 0.0001.& Microbe 6, 409–421, November 19, 2009 ª2009 Elsevier Inc. 415
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Tetherin Antagonism by Primate Lentivirusestetherin antagonist because Vpus from SIVgsn, SIVmus, and
SIVmon were only active against monkey tetherins, and those
from HIV-1 group M were only effective against ape and human
tetherins (Figure 3B). In comparison, host-specific adaptation
seems less important for CD4 downmodulation because the
great majority of primate lentiviral Vpu and Nef proteins is active
against human CD4 (Figure 2; Schindler et al., 2006). Second, we
found that SIVcpz employs Nef rather than Vpu to antagonize
tetherin (Figures 3C and 4C). This finding was unexpected given
that the vpu genes of SIVcpz, SIVgsn, SIVmus, and SIVmon
share a common ancestor (Schindler et al., 2006) and because
previous studies suggested that only SIVs that do not contain
a vpu gene use Nef to antagonize tetherin (Jia et al., 2009; Zhang
et al., 2009). Third, we found that SIV Nefs generally fail to coun-
teract HU tetherin because a deletion in the TM domain of the
human restriction factor disrupts its susceptibility to Nef
Figure 5. Titration of Antitetherin Antagonism
(A and B) Virus release from 293T cells following transfection with 2 mg of a DVpu/DNef proviral NL4-3 construct, 500 ng of SIV (A) or HIV-1 (B) Vpu (color coded
red) or Nef (color coded blue) expression constructs, and varying amounts of plasmids expressing the tetherin molecules from the respective host species. Infec-
tious virus was determined by infection of TZM-bl indicator cells (top), and p24 ELISA (bottom) is shown as a percentage of that detected in the absence of tetherin
(100%). All infections shown in (A–C) were performed in triplicate, and the results were confirmed in an independent experiment.
(C) HIV-1 O Nefs are inactive against HU tetherin. The assays were performed as described in (A) and (B). Shown are average values obtained using seven group O
(HJ428, HJ036, HJ736, HJ100, HJ256, 13127, and 8161) and three SIVcpz Ptt (Gab1, MT145, and MB897) nef alleles.416 Cell Host & Microbe 6, 409–421, November 19, 2009 ª2009 Elsevier Inc.
Cell Host & Microbe
Tetherin Antagonism by Primate LentivirusesFigure 6. Hypothetical Model of Tetherin-Driven Vpu and Nef Evolution
(A) Schematic of the acquisition of vpu and the subsequent transfer of vpu and nef genes from monkeys to chimpanzees and to humans by zoonotic primate
lentiviral transmissions. The events that led to the emergence of pandemic HIV-1 group M are indicated by thick lines. Nef-mediated tetherin antagonism is indi-
cated by blue lines and Vpu-mediated tetherin antagonism by red lines. The bottom panel summarizes the results of the present study and previous data on Nef
function. Note that the top panel is hypothetical, as the ancient vpu and nef genes are not available for analysis.
(B) Tetherin-driven evolution of Vpu and Nef function. Nef is present in all primate lentiviruses and interacts with the cytoplasmic tails (CTs) of tetherin and CD4.
Vpu was initially acquired by a precursor of SIVgsn/mus/mon and also targets the CT of CD4 but antagonizes tetherin by interacting with its transmembrane (TM)
domain. The vpu-containing precursor of SIVgsn/mon/mus (top-left) recombined with that of SIVrcm (bottom-left) in chimpanzees and the resulting recombinant
virus, i.e., SIVcpz, was subsequently transmitted to humans. Because Nef and Vpu inhibit tetherin in a species-specific manner, they were most likely initially
poorly active against CPZ tetherin. Subsequently, Nef evolved to become an effective tetherin antagonist in chimpanzees (middle). Upon cross-species trans-
mission of SIVcpz to humans, however, this Nef function was most likely disrupted by a unique deletion in the CT of the human restriction factor. Subsequently,
Vpu evolved to counteract HU tetherin during the emergence of pandemic HIV-1 M strains (top-right). In comparison, HIV-1 O Vpus remained poor tetherin antag-
onists (middle-right), and those from HIV-1 N lost the CD4 degradation activity (bottom-right). Matching colors indicate that Vpu and Nef recognize their TM and
CT interaction sites in the tetherin molecules. Broken gray arrows indicate disrupted or impaired activities.(Figure 4A) (Jia et al., 2009; Zhang et al., 2009). Together, these
findings suggest that tetherin poses a significant, albeit not
insurmountable, barrier to transmission of nonhuman primate
lentiviruses to humans. Moreover, it seems that only theCell Hostpandemic HIV-1 M group has entirely cleared this hurdle
because its Vpu protein evolved to become an effective tetherin
antagonist yet maintained its ability to degrade CD4. We there-
fore speculate that the acquisition of a fully functional Vpu& Microbe 6, 409–421, November 19, 2009 ª2009 Elsevier Inc. 417
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Tetherin Antagonism by Primate Lentivirusesprotein by the main group of HIV-1 contributed to the global
spread of the AIDS pandemic.
Switching between Nef- and Vpu-Mediated Antagonism
of Tetherin May Have Facilitated Primate Lentiviral
Zoonoses
It may seem surprising that SIVcpz uses Nef to antagonize teth-
erin but switched to use Vpu following transmission to humans.
Although further studies are necessary to fully elucidate the
evolution of Vpu and Nef functions, a possible scenario is out-
lined in Figure 6. Recent data show that some primate lentivi-
ruses that do not encode a vpu gene use Nef to antagonize teth-
erin (Jia et al., 2009; Zhang et al., 2009). Our observation that
Vpus from SIVgsn, SIVmus, and SIVmon are all capable of coun-
teracting their cognate tetherin suggests that this function was
already present in the vpu-containing common ancestor of these
viruses (Figure 6B, top-left). Evolutionary analyses indicate that
SIVcpz received vpu from the precursor of the SIVgsn/mus/
mon lineage, whereas its nef gene is derived from the SIVrcm
lineage (Bailes et al., 2003; Schindler et al., 2006). Thus, during
the adaptation of SIVcpz to its chimpanzee host, either Nef or
Vpu could have served as the tetherin antagonist. Because
both Nef and Vpu antagonize tetherin in a host-specific manner,
it is likely that they were initially both only poorly active against
the CPZ tetherin (Figure 6B, middle). Our data show that Nef
subsequently evolved to become an effective antagonist of
CPZ tetherin, possibly because the cytoplasmic tail (CT) of the
chimpanzee tetherin differs less from that of monkey tetherins
than the TM domain, which governs susceptibility to Vpu
(Figure 3A). Furthermore, the recombinant virus that comprises
SIVcpz (Bailes et al., 2003) may have had a selective advantage
over its nonmosaic precursors because its Vpu was capable of
degrading CD4, whereas its Nef was capable of exerting an anti-
tetherin activity. Upon cross-species transmission of SIVcpz to
humans, however, the Nef-mediated tetherin antagonism was
lost, most likely because a deletion in the cytoplasmic domain
of the human tetherin abrogated its sensitivity to Nef. This dele-
tion, which may have evolved in humans following encounters
with other pathogens, made it difficult, if not impossible, for
Nef to restore its antitetherin function. Hence, none of the 14
HIV-1 group M, N, and O Nefs that we tested had an appreciable
activity against HU tetherin. In contrast, the SIVgor Nef was able
to adapt to antagonize the GOR tetherin, most likely because
that restriction factor differs from that of CPZ only by two amino
acid substitutions in the CT domain. Consistent with this hypoth-
esis are recent findings showing that SIVsmm and SIVmac Nefs
are antagonists of monkey, but not human, tetherin (Jia et al.,
2009; Zhang et al., 2009). Furthermore, HIV-2, which originated
from SIVsmm, appears to use Env to facilitate the release of
progeny virions from human cells (Bour and Strebel, 1996),
although it remains to be elucidated whether this effect is due
to Env-mediated tetherin antagonism. Our data show that the
HIV-1 group M Vpu evolved to become an effective antagonist
of HU tetherin (Figure 6B, top-right). Thus, the flexibility to switch
between Nef and Vpu (which is lacking in HIV-2) to counteract
tetherin may have facilitated two cross-species transmission
events that may otherwise have been less successful: (1) the
transmission of SIVgsn/mus/mon to chimpanzees and (2) the
transmission of SIVcpz to humans (Figure 6).418 Cell Host & Microbe 6, 409–421, November 19, 2009 ª2009 ElsMultifunctionality of Accessory Proteins May Increase
the Potential for Cross-Species Transmission
of Primate Lentiviruses
In contrast to their effect on tetherin, the ability of SIV Vpus to
degrade CD4 has been well preserved, and this is also true for
most SIV Nef proteins (Schindler et al., 2006). Thus, at least
two primate lentiviral accessory genes, i.e., nef and vpu, that
antagonize host restriction factors in a species-specific manner
also have activities that seem largely independent of the host
species. It thus seems beneficial for primate lentiviruses to
target antiviral factors by proteins that exhibit functional plas-
ticity. A viral gene encoding a product that becomes entirely
nonfunctional and cannot readily adapt to a new host environ-
ment after cross-species transmission is likely prone to elimina-
tion by the rapid accumulation of mutations. However, genes
encoding proteins capable of performing multiple functions,
including at least one that is not species specific, will be main-
tained and may evolve to regain lost activities, sometimes
perhaps even at the cost of losing another activity. The acquisi-
tion of antitetherin activity by HIV-1 group M Vpus and the loss
of anti-CD4 activity by HIV-1 group N Vpus may represent
examples of this.
Tetherin May Represent a Barrier for Cross-Species
Transmissions of SIVs to Humans
Although the specificity of the Vpu/tetherin interaction resembles
that of other antiretroviral host restriction factors and their viral
antagonist, such as APOBEC3G and Vif (Gaddis et al., 2004;
Sawyer et al., 2004; Schro¨felbauer et al., 2004; Zennou and Bien-
iasz, 2006), there is one important difference: other restriction
factors such as APOBEC3G and TRIM5a are unlikely to pose
a barrier to cross-species transmission of SIVcpz from chimpan-
zees to humans. Specifically, the SIVcpz Vif protein is fully
capable of eliminating the antiviral activity of human APOBEC3G
(Gaddis et al., 2004), and the SIVcpz capsid is not susceptible to
restriction by human TRIM5a (Kratovac et al., 2008). Altogether,
these previous studies suggested that SIVcpz did not have to
overcome a major species barrier to transmission to humans
because chimpanzees and humans are genetically closely
related. Our finding that SIVcpz Vpus and Nefs were generally
poorly active in antagonizing HU tetherin challenges this dogma
and strongly suggests that tetherin constitutes a significant
barrier to transmission. Our data also provide compelling
evidence that host-specific adaptation allowed pandemic HIV-1
M strains to overcome this restriction because their Vpu protein
gained antitetherin activity while maintaining its ability to
degrade CD4. In the absence of such adaptation, SIVcpz strains
that have crossed the species barrier may not spread efficiently.
This may explain why just one of three independent chimpanzee-
to-human transmissions of SIVcpz has led to a pandemic. Our
finding that Vpus from all group M clades are capable of antag-
onizing tetherin suggests that this function was acquired early in
the evolution of HIV-1 group M. Moreover, the ten vpu alleles
from transmitted/founder HIV-1 strains that are responsible for
productive infection in humans all antagonized tetherin. In
contrast, Vpu proteins of HIV-1 group O are poor tetherin antag-
onists, and this is also true for this group’s Nef proteins. It will
thus be interesting to investigate whether HIV-1 O has evolved
other mechanisms to counteract this restriction factor (similarevier Inc.
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exhibit Vpu-mediated antitetherin activity (Figure 3C) but appear
to have lost the CD4 degradation function (Figure 2B). Thus,
imperfect adaptation of HIV-1 O and N to the human host may
explain why they have spread substantially less efficiently in
the human population than has HIV-1 M.
Conclusions
In summary, our data suggest that evolutionary switches
between Nef- and Vpu-mediated tetherin antagonism facilitated
the cross-species transmission that ultimately led to the emer-
gence of pandemic HIV-1 strains. The differences in HIV-1 group
M, O, and N Vpu function that are identified here should provide
important insights into the role of Vpu and tetherin antagonism in
virus transmission and pathogenesis. It has been previously
shown that the primate lentiviral lineage that gave rise to HIV-1
lost its ability to suppress T cell activation (Schindler et al.,
2006). Thus, HIV-1 may need a particularly effective tetherin
antagonist for effective virus release because it induces higher
levels of inflammation (and thus possibly tetherin) than does
nonpathogenic natural SIV infections (Kirchhoff, 2009). Finally,
the present report shows that—with respect to Nef and Vpu
function—SIVgsn, SIVmon, and SIVmus more closely resemble
HIV-1 M than does SIVcpz or other known SIVs. Thus, studies
of these natural SIV infections may provide relevant insights
into the pathogenesis of AIDS in humans.
EXPERIMENTAL PROCEDURES
Vpu, Nef, and Tetherin Expression Vectors
Constructs expressing N terminally HA-tagged tetherins have been described
previously (Neil et al., 2008; McNatt et al., 2009). Vpu alleles from the different
subtypes of HIV-1 M and some tetherin variants were chemically synthesized
(GenScript) (Tables S1 and S2). Cloning of vpu, nef, and tetherin alleles into the
bi-cistronic CMV-based pCGCG expression vector coexpressing the green
fluorescent protein (GFP) was essentially performed as described previously
(Greenberg et al., 1998; Schindler et al., 2003). See the Supplemental Experi-
mental Procedures for details.
Proviral HIV-1 Constructs
Generation of HIV-1 (NL4-3-based) proviral constructs containing a deletion of
nucleotides 3–120 of the vpu coding frame (DVpu) or functional nef genes fol-
lowed by an IRES and the eGFP gene (Nef/eGFP) has been described
previously (Rucker et al., 2004; Schindler et al., 2003, 2006). To generate
vpu-defective derivatives of the HIV-1 Nef/eGFP constructs (DVpu/Nef/
eGFP), restriction fragments encompassing the nef-IRES-eGFP region were
cloned into the DVpu proviral HIV-1 construct using the unique StuI and NotI
restriction sites in the env gene and the flanking vector sequence, respectively.
Proviral HIV-1 NL4-3 vectors expressing various vpu alleles independently of
overlapping env gene sequences were generated using splice-overlap exten-
sion PCR and standard cloning techniques as outlined in the Supplemental
Experimental Procedures. All PCR-derived inserts were sequenced to confirm
their accuracy.
Amplification of HIV-1 N and O nef and vpu Alleles
Blood samples were obtained from HIV-1-infected people living in Cameroon.
Genomic DNA was extracted from buffy coat, and fragments spanning the nef
and vpu genes were amplified by nested or seminested PCR. For details, see
the Supplemental Experimental Procedures.
Cell Culture and Transfections
Cells were cultured and transfected as described in the Supplemental Exper-
imental Procedures.Cell HostCD4 Cell Surface Expression
To determine the effect of Vpu on CD4 cell surface expression, 293T cells were
transfected by the calcium phosphate method in triplicate with 1 mg of a CD4
expression vector and 5 mg of pCGCG GFP/Vpu or GFP/Vpu-AU1 constructs
expressing GFP alone or together with untagged or tagged Vpus. At 2 days
posttransfection, CD4 expression was examined by FACS analysis as
described previously (Schindler et al., 2003). See Supplemental Experimental
Procedures for details.
Virus Yield and Infectivity Assays
Virus yield and infectivity assay were conducted in principle as described
(Mu¨nch et al., 2007; Neil et al., 2008; McNatt et al., 2009; Zhang et al.,
2009). For details, see the Supplemental Experimental Procedures.
Western Blot Analysis
The effects of Vpu and Nef on viral particle release were monitored as
described previously (Neil et al., 2008; McNatt et al., 2009; Zhang et al.,
2009). Expression of Vpu and tetherin, as well as of viral genes by proviral
NL4-3 UIE constructs, was examined as described in the Supplemental Exper-
imental Procedures.
Sequence Analyses
Tetherin and Vpu amino acid sequences were aligned using Multalign and
ClustalW2, respectively, followed by some manual editing.
Statistical Analysis
All statistical calculations were performed with a two-tailed unpaired Student’s
t test using Graph Pad Prism Version 5.0. P values < 0.05 were considered
significant. Correlations were calculated with the linear regression module.
ACCESSION NUMBERS
The accession numbers for all vpu, nef, and tetherin sequences analyzed in this
paper are listed in Tables S1, S2, and S3, respectively. GenBank accession
numbers of newly derived vpu, nef, and tetherin sequences are GQ925946
(CH040.c vpu), GQ925948 (CH058.c vpu), GQ925949 (CH077.t vpu),
GQ925947 (CH106.c vpu), GQ925939 (9435 vpu), GQ925937 (HJ001
vpu), GQ925943 (HJ100 vpu), GQ925941 (HJ162 vpu), GQ925940 (HJ256 vpu),
GQ925945 (HJ389 vpu), GQ925942 (HJ428 vpu), GQ925944 (HJ736
vpu), GQ925938 (HJ036 vpu), GQ925950 (2693BA vpu), GQ925951 (CK1.62
vpu), GQ925930 (HJ100 nef), GQ925932 (HJ162 nef), GQ925931 (HJ256
nef), GQ925936 (HJ389 nef), GQ925933 (HJ428 nef), GQ925935 (HJ736 nef),
GQ925934 (HJ036 nef), GQ925928 (2693BA nef), GQ925929 (CK1.62 nef),
GQ925927 (monNG1 nef), GQ925926 (GOR tetherin), GQ925923 (GSN
tetherin), GQ925925 (MUS tetherin), and GQ925924 (L-MON tetherin).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Results, Supplemental Experi-
mental Procedures, nine figures, and three tables and can be found with this
article online at http://www.cell.com/cell-host-microbe/supplemental/S1931-
3128(09)00323-0.
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